You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

You are here

Inflammatory Bowel Disease

The PMC reviewed relevant performance measures and makes the following recommendations.

November 2018 printable version of recommendations.
Printable version of the recommendations.

ACP supports this measure.

ID# MIPS 275

More Information

Assessment of Hepatitis B Virus (HBV) Status before Initiating Anti-Tumor Necrosis Factor (TNF) Therapy

Percentage of patients aged 18 years and older with a diagnosis of inflammatory bowel disease (IBD) who had Hepatitis B Virus (HBV) status assessed and results interpreted within one year prior to receiving a first course of anti-TNF (tumor necrosis factor) therapy. 
Date Reviewed: November 4, 2018

ACP does not support this measure.

ID# QPP 271

More Information

IBD: Preventive Care: Corticosteroid Related Iatrogenic Injury-Bone Loss Assessment

Percentage of patients aged 18 years and older with an inflammatory bowel disease encounter who were prescribed prednisone equivalents greater than or equal to 10 mg/day for 60 or greater consecutive days or a single prescription equating to 600mg prednisone or greater for all fills and were documented for risk of bone loss once during the reporting year or the previous calendar year.
Date Reviewed: November 19, 2017